Citations

Mayo Clinic

Clear

1581 citation(s) found for "Wu, Kelly L".

Invited commentary
Kelly, Keith A.

World Journal of Surgery | August 13, 2005 | Volume: 16 | Issue: 6 | Pages: 1115-1116

10.1007/bf02067072 Get It

Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732
Niell, Harvey B., Herndon, James E. , Miller, Antonius A., Watson, Dorothy, Sandler, Alan B., Kelly, Karen , Marks, Randolph S., Perry, Micheal C., Ansari, Rafat , Otterson, G A, Ellerton, John , Green, Mark R., Vokes, Everett E. , Kelly, Karen

Journal of Clinical Oncology | May 27, 2005 | Volume: 23 | Issue: 16 | Pages: 3752-3759

10.1200/jco.2005.09.071 | PMID 15923572 Get It

Purpose To determine, in a randomized comparison, whether the addition of paclitaxel to etoposide and cisplatin improves the time to progression and overall survival in patients with extensive small-cell lung cancer (SCLC) compared with standard etoposide and cisplatin and to compare the regimens' toxicity. Patients and Methods Eligible patients (N = 587) with untreated extensive SCLC were randomly assigned to receive either cisplatin 80 mg/m2 on day 1 and etoposide 80 mg/m2 on days 1 through 3 administered every 3 weeks for six cycles (EP) or cisplatin 80 mg/m2 on day 1, paclitaxel 175 mg/m2 over 4 hours on day 1, and etoposide 80 mg/m2 on days 1 to 3 followed by recombinant human granulocyte colony-stimulating factor on days 4 to 18 administered every 3 weeks for six cycles (PET). Results Reporting of demographics, response, and survival included 565 patients, of whom 282 were randomly assigned to receive EP and 283 were assigned to receive PET. Overall response rates were 68% for the EP arm and 75% for the PET arm. Median failure-free survival time was 5.9 months for the EP arm and 6 months for the PET arm (P = .179). Median overall survival time was 9.9 months for patients on EP and 10.6 months for patients on PET (P = .169). Toxic deaths occurred in 2.4% of the patients on EP and 6.5% of patients on PET. Conclusion PET did not improve the time to progression or survival in patients with extensive SCLC compared with EP alone and was associated with unacceptable toxicity.
Invited commentary
Kelly, Keith A.

World Journal of Surgery | May 8, 2005 | Volume: 14 | Issue: 5 | Pages: 599-599

10.1007/bf01658799 Get It

Motor function of the ileal J pouch and its relation to clinical outcome after ileal pouch‐anal anastomosis
O’Connell, P. R. , Pembérton, John H., Kelly, Keith A.

World Journal of Surgery | May 8, 2005 | Volume: 11 | Issue: 6 | Pages: 735-741

10.1007/bf01656596 | PMID 3324500 Get It

AbstractThe motor function of the ileal J pouch after ileal pouch‐anal anastomosis has a key role in the clinical outcome. The pouch forms a neorectum that aids in the maintenance of reasonable continence. The maximum capacity of the pouch (mean, 320 ml) is similar to that of the healthy rectum (330 ml). The pouch accommodates to distension, keeping intrapouch pressure low as the pouch gradually fills with stool. The change in pouch volume with each change in pressure (15 ml/mm Hg) approximates that of the healthy rectum (19 ml/mm Hg). When a threshold volume of about 150 ml is reached, large‐amplitude (>25 mm Hg), prolonged (40–60 sec), propulsive waves appear in the pouch. They initiate the call to stool. With continuing distention of the pouch to its functional capacity, which is about 200 ml, reflux of stool into the distal ileum begins, the large pressure waves become more frequent, and the urge for defecation more intense. Defecation is voluntary, spontaneous, and rapid (11 ml/sec), with the pouch and distal ileum emptying concurrently. About 60% of the pouch content, a volume of about 100 ml of stool, is discharged with each bowel movement. The greater the threshold volume and the more complete the evacuation, the fewer the bowel movements per day. After evacuation, the large pressure waves subside, and the next cycle of pouch filling and emptying begins.
Giant gastric and duodenal ulcers: A population‐based study with a comparison to nongiant ulcers
Gustavsson, Sven, Kelly, Keith A., Hench, Victoria S., Melton, L. Joseph

World Journal of Surgery | May 8, 2005 | Volume: 11 | Issue: 3 | Pages: 333-338

10.1007/bf01658111 | PMID 3604241 Get It

AbstractAmong 454 operations done for peptic ulcer between 1956 and 1985 on residents of Rochester, Minnesota, U.S.A. in whom ulcer size could be determined accurately, 50 operations (11% of the total) were performed for giant ulcers and 404 (89%) for nongiant ulcers. The annual operation rate per 100,000 residents for giant ulcer did not clearly decline during the 30‐year period in contrast to the dramatic fall in operation rates for nongiant ulcers. Nonetheless, the ratio of operation rates for giant ulcer compared to nongiant ulcer changed relatively little. Giant ulcers required emergency operation for massive bleeding more often than nongiant ulcers. Also, giant ulcers presented with unusual and severe complications such as gastrocolic fistula. Survival after surgery for giant ulcer was poorer than survival after an operation for nongiant ulcer. We conclude that giant ulcers are operated on somewhat less often today than in the past, while operations for nongiant ulcers are much less frequent. The giant ulcers that are operated on, however, are more prone to massive bleeding and are associated with poorer postoperative survival than their nongiant counterparts.
Human Leukocyte Antigen-DQ8 Transgenic Mice: a Model To Examine the Toxicity of Aerosolized Staphylococcal Enterotoxin B
Roy, Chad J. , Warfield, Kelly L. , Welcher, Brent, Gonzales, Raoul, Larsen, Thomas , Hanson, Julie A., David, Chella S., Krakauer, Theresa, Bavari, Sina

Infection and Immunity | March 22, 2005 | Volume: 73 | Issue: 4 | Pages: 2452-2460

10.1128/iai.73.4.2452-2460.2005 | PMID 15784591 Get It

ABSTRACTStaphylococcal enterotoxins (SEs) belong to a large group of bacterial exotoxins that cause severe immunopathologies, especially when delivered as an aerosol. SEs elicit the release of lethal amounts of cytokines by binding to major histocompatibility complex (MHC) class II and cross-linking susceptible T-cell receptors. Efforts to develop effective therapeutic strategies to protect against SEs delivered as an aerosol have been hampered by the lack of small animal models that consistently emulate human responses to these toxins. Here, we report that human leukocyte antigen-DQ8 (HLA-DQ8) transgenic (Tg) mice, but not littermate controls, succumbed to lethal shock induced by SEB aerosols without potentiation. Substantial amounts of perivascular edema and inflammatory infiltrates were noted in the lungs of Tg mice, similar to the pathology observed in nonhuman primates exposed by aerosol to SEB. Furthermore, the observed pathologies and lethal shock correlated with an upsurge in proinflammatory cytokine mRNA gene expression in the lungs and spleens, as well as with marked increases in the levels of proinflammatory circulating cytokines in the Tg mice. Unlike the case for littermate controls, telemetric evaluation showed significant hypothermia in Tg mice exposed to lethal doses of SEB. Taken together, these results show that this murine model will allow for the examination of therapeutics and vaccines developed specifically against SEB aerosol exposure and possibly other bacterial superantigens in the context of human MHC class II receptors.
Proteomic analysis of mantle-cell lymphoma by protein microarray
Leontovich, Alexey A. , Loegering, David A., Dai, Nga T., Krajnik, Kelly L., Stenson, Mary, Melhem, Mona F., Novak, Anne J. , Ansell, Stephen M. , Ghobrial, Irene M. , McCormick, Daniel , Kaufmann, Scott H. , Witzig, Thomas E.

Blood | January 14, 2005 | Volume: 105 | Issue: 9 | Pages: 3722-3730

10.1182/blood-2004-10-3999 | PMID 15650054 Get It

Abstract Mantle-cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphoma (NHL) that behaves aggressively and remains incurable. In order to understand the pathogenesis of MCL and design new therapies, it is important to accurately analyze molecular changes in pathways dysregulated in MCL. We used antibody microarrays to compare patterns of protein expression between CD19+ purified B lymphocytes from normal tonsil and 7 cases of histologically confirmed MCL. Protein overexpression was defined as a higher than 1.3-fold or 2-fold increase in at least 67% of tumor samples compared with normal B-cell control. Of the polypeptides, 77 were overexpressed using the higher than 1.3-fold cutoff, and 13 were overexpressed using the 2-fold cutoff. These included cell cycle regulators (regulator of chromosome condensation 1 [RCC1], murine double minute 2 [MDM2]), a kinase (citron Rho-interacting kinase [CRIK]), chaperone proteins (heat shock 90-kDa protein [Hsp90], Hsp10), and phosphatase regulators (A-kinase anchor protein 1 [AKAP149], protein phosphatase 5 [PP5], and inhibitor 2). The elevated expression of some of these polypeptides was confirmed by immunoblotting and immunohistochemistry, whereas elevated expression of others could not be confirmed, illustrating the importance of confirmatory studies. This study describes a novel technique that identifies proteins dysregulated in MCL.
Impact of therapeutic endoscopy on the treatment of bleeding duodenal ulcers: 1980–1990
Miller, Alexander R., Farnell, Michael B., Kelly, Keith A., Gostout, Christopher J., Benson, Joanne T.

World Journal of Surgery | December 10, 2004 | Volume: 19 | Issue: 1 | Pages: 89-94

10.1007/bf00316985 | PMID 7740816 Get It

AbstractTherapeutic endoscopy (TE) has provided a new means for treating peptic ulcer disease, prompting a reevaluation of surgery's role. The aim of this study was to determine if surgical therapy of bleeding duodenal ulcers has changed since the advent of TE. This retrospective review involved consecutive time periods during which TE was (1985–1990) and was not (1980–1984) widely available. Exclusion criteria were prior gastric surgery, nonpeptic conditions, and untreated ulcers. Inclusion standards were met by 252 patients (180 men, 72 women) whose mean age was 67 years. Patients were grouped by the initial therapeutic intervention. Groups were similar in age, medical condition (mean APACHE II score 16), and morbidity. Seventy‐five patients had surgery alone during 1980–1984 and 38 during 1985–1990. TE was initially performed on 134 patients during 1985–1990. Bleeding (n=30) and perforation (n=1) prompted emergent operation in 23% of cases following TE. Thus 69 (38+31) patients underwent surgery between 1985 and 1990. Preprocedure transfusions averaged 4.1 units in the endoscopic group and 8.2 units in the operative groups (p<0.0001). Disagreement existed between the endoscopic and surgical descriptions of ulcer location in 53% of cases. Emergent surgery was required in 45% of hemodynamically unstable patients versus 14% of stable patients who initially underwent TE (p<0.0001). Sixty‐one percent of incompletely visualized TE‐treated lesions required operation, and 18% of well visualized ulcers underwent operation (p<0.0001). Hospital mortality was similar (8% versus 16%) in the endoscopic and operated groups (p=0.7). Mean follow‐up was 540 days. The number of operations performed for bleeding duodenal ulcer did not change significantly during the TE era, and a significant subset (23%) of endoscopically treated patients required surgical therapy. TE failure was portended by hemodynamic instability or incomplete endoscopic visualization.
The Limited Value of Cytoreductive Surgery in Elderly Patients with Malignant Gliomas
Hunt, Cathy, Kelly, Patrick J.

Neurosurgery | September 2, 2004 | Volume: 34 | Issue: 1 | Pages: 62-67

10.1097/00006123-199401000-00009 Get It